A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

Condition:   Mild to Moderate Atopic Dermatitis Interventions:   Drug: IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment;   Drug: IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment;   Drug: IN-A002 Ointment 1% or IN-A002 Placebo Ointment;   Drug: IN-A002 Ointment 3% or IN-A002 Placebo Ointment;   Drug: IN-A002 Ointment 5% or IN-A002 Placebo Ointment;   Dr ug: IN-A002 Ointment 1%;   Drug: IN-A002 Ointment 3%;   Drug: Elidel Cream 1% (pimecrolimus) Sponsor:   HK inno.N Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials